{"id":"https://openalex.org/W7220664753","doi":"https://doi.org/10.3389/fimmu.2026.1932448","title":"Ravulizumab in neuromyelitis optica spectrum disorder: first clinical experience in Chile","display_name":"Ravulizumab in neuromyelitis optica spectrum disorder: first clinical experience in Chile","publication_year":2026,"publication_date":"2026-10-06","ids":{"openalex":"https://openalex.org/W7220664753","doi":"https://doi.org/10.3389/fimmu.2026.1932448","pmid":"https://pubmed.ncbi.nlm.nih.gov/42903195","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13680220"},"language":"en","primary_location":{"id":"doi:10.3389/fimmu.2026.1932448","doi":"https://doi.org/10.3389/fimmu.2026.1932448","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.1932448","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1932448/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1932448/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5135060908","display_name":"Tamara Santib\u00e1\u00f1ez","orcid":"https://orcid.org/0009-0009-4022-8310","observed_orcids":["https://orcid.org/0009-0009-4022-8310"]},"institutions":[{"id":"https://openalex.org/I2801797538","display_name":"Cl\u00ednica Alemana","ror":"https://ror.org/028ynny55","country_code":"CL","type":"healthcare","lineage":["https://openalex.org/I2801797538"]},{"id":"https://openalex.org/I4405273265","display_name":"Hospital Cl\u00ednico Dra. Elo\u00edsa D\u00edaz I. La Florida","ror":"https://ror.org/05jrjxj02","country_code":"CL","type":"healthcare","lineage":["https://openalex.org/I4210109244","https://openalex.org/I4210122724","https://openalex.org/I4405273265"]}],"countries":["CL"],"is_corresponding":false,"raw_author_name":"Tamara Santib\u00e1\u00f1ez","raw_affiliation_strings":["Hospital Dra. Elo\u00edsa D\u00edaz Inzunza, La Florida","Neuroimmunology Unit, Department of Neurology, Cl\u00ednica Alemana de Santiago"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Dra. Elo\u00edsa D\u00edaz Inzunza, La Florida","institution_ids":["https://openalex.org/I4405273265"]},{"raw_affiliation_string":"Neuroimmunology Unit, Department of Neurology, Cl\u00ednica Alemana de Santiago","institution_ids":["https://openalex.org/I2801797538"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090579370","display_name":"Jos\u00e9 Vald\u00e9s","orcid":"https://orcid.org/0000-0002-7740-8659","observed_orcids":["https://orcid.org/0000-0002-7740-8659"]},"institutions":[{"id":"https://openalex.org/I2801797538","display_name":"Cl\u00ednica Alemana","ror":"https://ror.org/028ynny55","country_code":"CL","type":"healthcare","lineage":["https://openalex.org/I2801797538"]}],"countries":["CL"],"is_corresponding":false,"raw_author_name":"Jos\u00e9 Miguel Vald\u00e9s","raw_affiliation_strings":["Cl\u00ednica RedSalud","Neuroimmunology Unit, Department of Neurology, Cl\u00ednica Alemana de Santiago"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cl\u00ednica RedSalud","institution_ids":[]},{"raw_affiliation_string":"Neuroimmunology Unit, Department of Neurology, Cl\u00ednica Alemana de Santiago","institution_ids":["https://openalex.org/I2801797538"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113580989","display_name":"C\u00e9sar Ram\u00f3n Romero","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131012","display_name":"Hospital Cl\u00ednico de la Universidad de Chile","ror":"https://ror.org/02xtpdq88","country_code":"CL","type":"healthcare","lineage":["https://openalex.org/I4210131012"]}],"countries":["CL"],"is_corresponding":false,"raw_author_name":"C\u00e9sar Romero","raw_affiliation_strings":["Cl\u00ednica RedSalud","Hospital Cl\u00ednico Universidad de Chile"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cl\u00ednica RedSalud","institution_ids":[]},{"raw_affiliation_string":"Hospital Cl\u00ednico Universidad de Chile","institution_ids":["https://openalex.org/I4210131012"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112158918","display_name":"Manuel Fruns Q.","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I162096671","display_name":"Universidad de Los Andes","ror":"https://ror.org/02mhbdp94","country_code":"CO","type":"education","lineage":["https://openalex.org/I162096671"]},{"id":"https://openalex.org/I4210086110","display_name":"Cl\u00ednica Las Condes","ror":"https://ror.org/00j5bwe91","country_code":"CL","type":"healthcare","lineage":["https://openalex.org/I4210086110"]},{"id":"https://openalex.org/I4210143738","display_name":"Universidad de Los Andes","ror":"https://ror.org/04pqpvr75","country_code":"BO","type":"education","lineage":["https://openalex.org/I4210143738"]}],"countries":["BO","CL","CO"],"is_corresponding":false,"raw_author_name":"Manuel Fruns","raw_affiliation_strings":["Cl\u00ednica Las Condes","Cl\u00ednica Universidad de los Andes"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cl\u00ednica Las Condes","institution_ids":["https://openalex.org/I4210086110"]},{"raw_affiliation_string":"Cl\u00ednica Universidad de los Andes","institution_ids":["https://openalex.org/I162096671","https://openalex.org/I4210143738"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5082131396","display_name":"Lorna Galleguillos","orcid":"https://orcid.org/0000-0003-3131-6246","observed_orcids":["https://orcid.org/0000-0003-3131-6246"]},"institutions":[{"id":"https://openalex.org/I2801797538","display_name":"Cl\u00ednica Alemana","ror":"https://ror.org/028ynny55","country_code":"CL","type":"healthcare","lineage":["https://openalex.org/I2801797538"]},{"id":"https://openalex.org/I4210155385","display_name":"Cl\u00ednica D\u00e1vila","ror":"https://ror.org/04gyvnw24","country_code":"CL","type":"healthcare","lineage":["https://openalex.org/I4210155385"]}],"countries":["CL"],"is_corresponding":true,"raw_author_name":"Lorna Galleguillos","raw_affiliation_strings":["Cl\u00ednica D\u00e1vila","Neuroimmunology Unit, Department of Neurology, Cl\u00ednica Alemana de Santiago"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cl\u00ednica D\u00e1vila","institution_ids":["https://openalex.org/I4210155385"]},{"raw_affiliation_string":"Neuroimmunology Unit, Department of Neurology, Cl\u00ednica Alemana de Santiago","institution_ids":["https://openalex.org/I2801797538"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5082131396"],"corresponding_institution_ids":["https://openalex.org/I2801797538","https://openalex.org/I4210155385"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.74688776,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":"1932448","last_page":"1932448"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11735","display_name":"Peripheral Neuropathies and Disorders","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10993","display_name":"Complement system in diseases","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ravulizumab","display_name":"ravulizumab","score":0.9430000185966492},{"id":"https://openalex.org/keywords/neuromyelitis-optica-spectrum-disorder","display_name":"neuromyelitis optica spectrum disorder","score":1.0},{"id":"https://openalex.org/keywords/aquaporin-4-antibodies","display_name":"aquaporin-4 antibodies","score":0.878000020980835},{"id":"https://openalex.org/keywords/c5a-receptor-inhibition","display_name":"C5a receptor inhibition","score":0.6169999837875366},{"id":"https://openalex.org/keywords/complement-inhibition","display_name":"complement inhibition","score":0.46700000762939453},{"id":"https://openalex.org/keywords/longitudinally-extensive-transverse-myelitis","display_name":"longitudinally extensive transverse myelitis","score":0.9110000133514404},{"id":"https://openalex.org/keywords/optic-neuritis","display_name":"optic neuritis","score":0.8970000147819519},{"id":"https://openalex.org/keywords/expanded-disability-status-scale","display_name":"Expanded Disability Status Scale","score":0.8080000281333923},{"id":"https://openalex.org/keywords/relapse-prevention","display_name":"relapse prevention","score":0.7990000247955322},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.4620000123977661},{"id":"https://openalex.org/keywords/chilean-patients","display_name":"Chilean patients","score":0.6800000071525574}],"concepts":[{"id":"https://openalex.org/C2781137167","wikidata":"https://www.wikidata.org/wiki/Q611458","display_name":"Neuromyelitis optica","level":3,"score":0.9283000230789185},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8763999938964844},{"id":"https://openalex.org/C2777185649","wikidata":"https://www.wikidata.org/wiki/Q202217","display_name":"Transverse myelitis","level":3,"score":0.6668999791145325},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.6395999789237976},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.595300018787384},{"id":"https://openalex.org/C2776572573","wikidata":"https://www.wikidata.org/wiki/Q972514","display_name":"Optic neuritis","level":3,"score":0.5889000296592712},{"id":"https://openalex.org/C2777154362","wikidata":"https://www.wikidata.org/wiki/Q7575316","display_name":"Spectrum disorder","level":2,"score":0.5791000127792358},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.569100022315979},{"id":"https://openalex.org/C2780892749","wikidata":"https://www.wikidata.org/wiki/Q929518","display_name":"Expanded Disability Status Scale","level":3,"score":0.49709999561309814},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4745999872684479},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.44440001249313354},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.41019999980926514},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.40220001339912415},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.39809998869895935},{"id":"https://openalex.org/C2777704947","wikidata":"https://www.wikidata.org/wiki/Q551085","display_name":"Myelitis","level":3,"score":0.39239999651908875},{"id":"https://openalex.org/C2779328510","wikidata":"https://www.wikidata.org/wiki/Q424242","display_name":"Acute disseminated encephalomyelitis","level":3,"score":0.3643999993801117},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3393000066280365},{"id":"https://openalex.org/C2778720950","wikidata":"https://www.wikidata.org/wiki/Q424972","display_name":"Prednisone","level":2,"score":0.33500000834465027},{"id":"https://openalex.org/C2781004633","wikidata":"https://www.wikidata.org/wiki/Q386119","display_name":"Natalizumab","level":3,"score":0.30970001220703125},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.29269999265670776},{"id":"https://openalex.org/C533803919","wikidata":"https://www.wikidata.org/wiki/Q30953","display_name":"Dengue fever","level":2,"score":0.2732999920845032},{"id":"https://openalex.org/C107130276","wikidata":"https://www.wikidata.org/wiki/Q133805","display_name":"Epidemiology","level":2,"score":0.26759999990463257},{"id":"https://openalex.org/C81182388","wikidata":"https://www.wikidata.org/wiki/Q353963","display_name":"Complication","level":2,"score":0.2524000108242035}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001323","descriptor_name":"Autoantibodies","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D001323","descriptor_name":"Autoantibodies","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D002677","descriptor_name":"Chile","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007074","descriptor_name":"Immunoglobulin G","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009471","descriptor_name":"Neuromyelitis Optica","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D009471","descriptor_name":"Neuromyelitis Optica","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009471","descriptor_name":"Neuromyelitis Optica","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051401","descriptor_name":"Aquaporin 4","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.3389/fimmu.2026.1932448","doi":"https://doi.org/10.3389/fimmu.2026.1932448","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.1932448","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1932448/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13680220","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13680220/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13680220/pdf/fimmu-17-1932448.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Immunol","raw_type":"Text"},{"id":"pmid:42903195","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42903195","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in immunology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:a020f088912e4e72a0373a369f2d9357","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/a020f088912e4e72a0373a369f2d9357","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Immunology, Vol 17 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fimmu.2026.1932448","doi":"https://doi.org/10.3389/fimmu.2026.1932448","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.1932448","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1932448/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7220664753.pdf","grobid_xml":"https://content.openalex.org/works/W7220664753.grobid-xml"},"referenced_works_count":24,"referenced_works":["https://openalex.org/W2053472907","https://openalex.org/W2112165124","https://openalex.org/W2119987649","https://openalex.org/W2120238028","https://openalex.org/W2129229339","https://openalex.org/W2151890979","https://openalex.org/W2343427124","https://openalex.org/W2463681628","https://openalex.org/W2764089668","https://openalex.org/W2893559337","https://openalex.org/W2943416206","https://openalex.org/W2972221943","https://openalex.org/W2991438804","https://openalex.org/W3012054652","https://openalex.org/W3037214622","https://openalex.org/W3045766891","https://openalex.org/W3088822708","https://openalex.org/W4206710086","https://openalex.org/W4323036933","https://openalex.org/W4385618224","https://openalex.org/W4401358413","https://openalex.org/W4411225546","https://openalex.org/W7129682476","https://openalex.org/W7164534305"],"related_works":["https://openalex.org/W7168179635","https://openalex.org/W4323036933","https://openalex.org/W4409228249","https://openalex.org/W4403206760","https://openalex.org/W4394598349","https://openalex.org/W7164229202","https://openalex.org/W4409609002","https://openalex.org/W7222981209","https://openalex.org/W7164534305","https://openalex.org/W4367305124"],"abstract_inverted_index":{"Background:":[0],"Neuromyelitis":[1],"optica":[2],"spectrum":[3],"disorder":[4],"(NMOSD)":[5],"is":[6],"a":[7,32,78,83,92,155,223,264,338],"neuroimmunological":[8],"astrocytopathy":[9],"mediated":[10],"by":[11,174],"anti-aquaporin-4":[12],"(AQP4-IgG)":[13],"antibodies":[14],"that":[15],"trigger":[16],"complement-dependent":[17],"cytotoxicity":[18],"and":[19,86,121,127,138,217,305,322,344,362,373],"activation":[20],"of":[21,101,161,214,226,267,341],"the":[22,27,46,52,62,106,182,247,251,314,355,376,386],"terminal":[23,34],"complement":[24,35],"cascade":[25],"in":[26,41,43,68,169,281,299,359],"central":[28],"nervous":[29],"system.":[30,389],"Ravulizumab,":[31],"long-acting":[33],"C5":[36],"inhibitor,":[37],"received":[38],"regulatory":[39],"approval":[40],"Chile":[42],"January":[44],"2025;":[45],"seven":[47],"patients":[48,102,149,171,193,205,283,307],"reported":[49,358],"here":[50],"represent":[51],"entire":[53],"nationally":[54],"treated":[55],"cohort":[56,99],"to":[57,269,301,320,378,382],"date.":[58],"Objectives:":[59],"To":[60],"describe":[61],"first":[63],"clinical":[64,122,234],"experience":[65],"with":[66,103,154,241,333,354,363],"ravulizumab":[67,330],"NMOSD":[69,104],"at":[70,158,309],"three":[71,306],"Chilean":[72,328,387],"centers":[73],"(Cl\u00ednica":[74],"Alemana":[75],"de":[76,90],"Santiago,":[77],"private":[79,84],"center,":[80,85],"Cl\u00ednica":[81],"D\u00e1vila,":[82],"Hospital":[87],"Cl\u00ednico":[88],"Universidad":[89],"Chile,":[91],"public":[93],"university":[94],"hospital).":[95],"Methods:":[96],"Retrospective,":[97],"multicenter":[98],"study":[100],"fulfilling":[105],"2015":[107],"International":[108],"Panel":[109],"for":[110],"NMO":[111],"Diagnosis":[112],"(IPND)":[113],"consensus":[114,365],"criteria":[115],"who":[116],"were":[117,141,152,236],"receiving":[118],"ravulizumab.":[119],"Demographic":[120],"characteristics,":[123],"AQP4-IgG":[124,166],"status,":[125],"baseline":[126,200,265,279],"follow-up":[128,225,340],"Expanded":[129],"Disability":[130],"Status":[131],"Scale":[132],"(EDSS)":[133],"scores,":[134],"treatment":[135,220],"indication,":[136],"relapses":[137,235,244],"adverse":[139,316],"events":[140],"analyzed":[142],"through":[143],"medical":[144],"chart":[145],"review.":[146],"Results:":[147],"Seven":[148],"(100%":[150],"female)":[151],"included,":[153],"mean":[156],"age":[157],"disease":[159,183],"onset":[160],"51.0":[162],"years":[163],"(range":[164,229],"38-69).":[165],"was":[167,185,202,219,284,313,331,345],"positive":[168],"all":[170],"(100%),":[172],"confirmed":[173],"cell-based":[175],"assay.":[176],"The":[177],"most":[178],"common":[179],"presentation":[180],"over":[181,337],"course":[184],"longitudinally":[186],"extensive":[187],"transverse":[188],"myelitis":[189],"(LETM;":[190],"7/7);":[191],"four":[192],"(57.1%)":[194],"also":[195],"developed":[196],"optic":[197],"neuritis.":[198],"Median":[199],"EDSS":[201,261,280,310],"6.0.":[203],"Five":[204],"had":[206,250],"previously":[207],"failed":[208],"rituximab,":[209],"one":[210,218],"discontinued":[211],"rituximab":[212,371],"because":[213,278],"active":[215],"cancer,":[216],"na\u00efve.":[221],"Over":[222],"median":[224,266,339],"15":[227,342],"months":[228,343],"4-24)":[230],"on":[231,367],"ravulizumab,":[232],"no":[233],"observed":[237],"(0/7":[238],"patients),":[239],"compared":[240],"approximately":[242],"4.5":[243],"expected":[245],"across":[246],"cohort's":[248],"person-time":[249],"pre-treatment":[252],"relapse":[253,335],"rate":[254],"continued":[255],"unchanged":[256],"(observed-vs-expected":[257],"analysis;":[258],"see":[259],"Results).":[260],"declined":[262],"from":[263],"6.0":[268],"2.5":[270],"(median":[271],"within-patient":[272],"change":[273],"1.5":[274],"points,":[275],"IQR":[276],"1.0-4.0);":[277],"several":[282],"recorded":[285],"during":[286],"or":[287],"shortly":[288],"after":[289,370],"an":[290],"acute":[291],"attack,":[292],"this":[293,326],"decrease":[294],"likely":[295],"reflects":[296],"post-attack":[297],"recovery":[298],"addition":[300],"any":[302],"disability-modifying":[303],"effect,":[304],"remained":[308],"\u22655.":[311],"Headache":[312],"only":[315],"event":[317],"(7/7),":[318],"mild":[319],"moderate":[321],"self-limited.":[323],"Conclusions:":[324],"In":[325],"real-world":[327],"cohort,":[329],"associated":[332],"complete":[334],"suppression":[336],"well":[346],"tolerated.":[347],"These":[348],"preliminary,":[349],"uncontrolled":[350],"observations":[351],"are":[352],"consistent":[353],"relapse-prevention":[356],"efficacy":[357],"pivotal":[360],"trials":[361],"regional":[364],"guidance":[366],"its":[368],"use":[369],"failure,":[372],"they":[374],"underscore":[375],"need":[377],"expand":[379],"equitable":[380],"access":[381],"complement-targeted":[383],"therapies":[384],"within":[385],"healthcare":[388]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-10-07T00:00:00"}